Advantages of Oral Enasidenib in IDH2-Mutated AML

preview_player
Показать описание
Hetty E. Carraway, MD, speaks to the advantages of the selective oral IDH2-inhibitor enasidenib (Idhifa) for patients with IDH2-mutant acute myeloid leukemia.

  1. Targeted Oncology
  2. targeted oncology
  3. oncology
  4. cancer
Рекомендации по теме
Advantages of Oral 0:02:11

Advantages of Oral Enasidenib in IDH2-Mutated AML

IDH Inhibitors for 0:08:50

IDH Inhibitors for AML

Enasidenib’s Role in 0:04:20

Enasidenib’s Role in IDH-Mutant Acute Myeloid Leukemia

Beat AML: promising 0:02:25

Beat AML: promising results with enasidenib for AML in the frontline

The efficacy and 0:04:24

The efficacy and safety of enasidenib plus azacitidine versus azacitidine monotherapy in mutant-...

Dr. Mims on 0:01:14

Dr. Mims on FDA Approval of Ivosidenib in Patients With AML

Rationale for Enasidenib 0:03:05

Rationale for Enasidenib in AML

Enasidenib in Relapsed/Refractory 0:04:05

Enasidenib in Relapsed/Refractory Mutant IDH2 AML

Beat AML Master 0:01:18

Beat AML Master sub-study: enasidenib and response-driven addition of azacitidine in IDH2m AML

AML: Identifying Practical 0:08:55

AML: Identifying Practical Concerns With Enasidenib

Dr. Al-Kali on 0:00:58

Dr. Al-Kali on FDA Approval of Enasidenib in AML

Is enasidenib plus 0:03:16

Is enasidenib plus azacitidine better than with azacitidine alone for AML patients?

Phase II trial 0:02:01

Phase II trial of enasidenib in IDH2-mutant MDS

Phase I Results 0:01:24

Phase I Results for Enasidenib in AML

Expert Explores Potential 0:01:26

Expert Explores Potential Role of Doublets and Triplets in IDH1-Mutant Acute Myeloid Leukemia

AML: Significance of 0:02:10

AML: Significance of the IDH2 Mutation

The next steps 0:01:19

The next steps for the IDH2 inhibitor drug enasidenib

Differentiation Syndrome and 0:02:55

Differentiation Syndrome and IDH1/2 Inhibitors

Enasidenib plus Azacitidine 0:04:55

Enasidenib plus Azacitidine Combination Therapy for Acute Myeloid Leukaemia

IDH inhibitors for 0:01:32

IDH inhibitors for AML and MDS

Enasidenib for IDH2-mutated 0:01:13

Enasidenib for IDH2-mutated MDS

Toxicity Management in 0:05:40

Toxicity Management in the Treatment of R/R AML

Targeting IDH1/2 in 0:06:10

Targeting IDH1/2 in AML

Enasidenib in mutant-IDH2 0:08:26

Enasidenib in mutant-IDH2 R/R AML: Results of a phase 1 dose-escalation and expansion study

welcome to shbcf.ru